The impact of specific pulmonary arterial hypertension therapy on cardiac fluorodeoxyglucose distribution in PET/MRI hybrid imaging–follow-up study

Kazimierczyk, Remigiusz; Szumowski, Piotr; Nekolla, Stephan G.; Malek, Lukasz A.; Blaszczak, Piotr; Hladunski, Marcin; Sobkowicz, Bozena; Mysliwiec, Janusz; Kaminski, Karol A.

doi:10.1186/s13550-023-00971-w

EJNMMI Research

Table 1 Basic characteristics of pulmonary arterial hypertension (PAH) group at baseline and two follow-up visits (after 24 and 48 months)

From: The impact of specific pulmonary arterial hypertension therapy on cardiac fluorodeoxyglucose distribution in PET/MRI hybrid imaging–follow-up study

	Baseline	FU-1	FU-2
Subjects, n	20*	20	16
CEP (deaths)		16 (4)	10 (4)
Age, years	49.2 ± 15.1	49.8 ± 14.9	50.1 ± 14.4
Sex (females), % (n)	70 (14)	70 (14)	81 (13)
WHO Class	2.1 ± 0.7	2.3 ± 0.7	2.2 ± 0.7
6 min walking test distance, m	404 ± 87.8	412 ± 77	420 ± 111
BNP, pg/ml	90.8 [46–282]	114 [77–245]	113 [76–252]
PAH etiology
Idiopathic/heritable PAH, % (n)	60 (12)	60 (12)	56 (9)
Connective tissue disease related PAH, % (n)	15 (3)	15 (3)	12 (2)
Congenital heart disease related PAH, % (n)	25 (5)	25 (5)	32 (5)
PAH specific therapy
Phosphodiesterase type 5 inhibitors, % (n)	38 (10)	10 (2)	12 (2)
Endothelin receptor antagonists, % (n)	11 (3)	15 (3)	0 (0)
Prostacyclins, % (n)	20 (5)	65 (13)	50 (8)
Phosphodiesteraze type 5 inhibitors + endothelin receptor antagonists, % (n)	31 (8)	10 (2)	38 (6)
Hemodynamics
Systolic pulmonary artery pressure, mm Hg	82.2 ± 29.2	78.2 ± 24.2	75.3 ± 32.3
Diastolic pulmonary artery pressure, mm Hg	33.8 ± 14.3	31.2 ± 13.9	29.43 ± 14
Mean pulmonary artery pressure, mm Hg	50.5 ± 18.3	42.8 ± 18.6^	32.6 ± 12.1^^
Pulmonary capillary wedge pressure, mm Hg	10.6 ± 2.5	9.73 ± 3	8.8 ± 2.8
Pulmonary vascular resistance, Wood units	8.9 ± 5.7	7.3 ± 4.7^	5.3 ± 2.8^^
Cardiac index, L/min/m²	2.5 ± 0.4	2.9 ± 0.4^	2.9 ± 0.6^^
Right atrium pressure, mm Hg	8.6 ± 3.6	8.1 ± 5.3	8 ± 5.3
RV parameters (MRI)
RV ejection fraction, %	45.1 ± 9.6	52.4 ± 12.9^
RV EDV/BSA, mL/m²	113.2 ± 24.5	106 ± 27
RV ESV/BSA, mL/m²	62.7 ± 22.7	50 ± 11
RV mass/BSA, g/m²	39.9 ± 13.9	39.2 ± 14.6
RV compacted myocardium thickness, mm	5.7 ± 1.5	5.2 ± 1.3
Pulmonary arterial compliance, mL/mm Hg	2.4 ± 1.8	3.2 ± 2.4^
Right ventricle stroke work index, gmm²/beat	20.6 ± 8.4	18.2 ± 7.5
Myocardial metabolism (PET)
SUV_RV	2.5 [1.4–5.5]	3.92 [1.6–8.1]
SUV_LV	3.5 [2.1–6.6]	5.7 [4.8–8.9]
SUV_RV/SUV_LV ratio	0.94 [0.48–1.38]	0.63 [0.41–1.16]

Data presented as mean ± SD (normal distribution; paired t-test was used to compare two variables) or median [IQR] (non-normal distribution; Wilcoxon signed rank test was used to compare two variables)
^*number of matched pairs of patients present at both baseline and FU-1 visits. ^ statistical significance (p < 0.05) (Wilcoxon signed rank test was used to compare matched (Baseline vs FU-1) values). ^^ statistical significance (p < 0.05) (Wilcoxon signed rank test was used to compare matched (Baseline vs FU-2) values)
BNP B-type natriuretic peptide, BSA Body surface area, CEP Clinical end-point, EDV End-diastolic volume, ESV End-systolic volume, FU Follow-up, LV Left ventricle, MRI Magnetic resonance imaging, PET Positron emission tomography, RV Right ventricle, SUV Standardized uptake value, WHO World Health Organisation

Back to article page